Modulation, not boosting
The popular "immune boosting" frame is misleading. A healthy immune system is calibrated, not maximized. Hyperactivity drives autoimmune disease, allergy, and chronic inflammation; underactivity drives infection susceptibility. The therapeutic goal of immune peptides is modulation — restoring appropriate response when the system has drifted in either direction. This is why peptides like Thymosin Alpha-1 are useful in both immunocompromised states (HIV, cancer chemotherapy) and inflammatory states (chronic hepatitis, certain autoimmune conditions): they push the system toward equilibrium rather than in one direction.
Thymosin Alpha-1
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland. It modulates T-cell differentiation, NK cell activity, and dendritic cell function. It is the most-clinically-validated immune peptide, with approval in many countries for hepatitis B, hepatitis C, and as an adjuvant for cancer immunotherapy (Goldstein and Garaci, review, 2010).
For research-use applications in healthy adults, Thymosin Alpha-1 is used as a maintenance immune modulator for people with chronic viral infections, recurrent infections, or as adjunctive support during cancer treatment. Standard protocol: 1.6 mg SC twice weekly, 8–12 week cycles, repeated as indicated.
LL-37
LL-37 is the only human cathelicidin antimicrobial peptide. It has direct antibacterial, antiviral, and antifungal activity, plus immunomodulatory effects on dendritic cells and macrophages. LL-37 is being investigated for chronic biofilm infections, antibiotic-resistant infections, and certain skin conditions (Vandamme et al., Cell Mol Immunol, 2012, PMID: 22921356).
Clinical evidence for direct supplementation is still emerging. Typical research dose: 100–300 mcg SC daily, 4–6 week courses.
KPV
KPV is the C-terminal tripeptide of alpha-MSH. Its primary effect is anti-inflammatory through NF-κB modulation. While not typically classified as an "immune peptide" per se, KPV's anti-inflammatory action is useful for the inflammatory side of immune dysregulation: autoimmune flares, IBD-spectrum conditions, chronic inflammation. Typical: 100–500 mcg SC daily.
Supporting peptides
BPC-157 has well-documented effects on gut mucosal integrity, which is a major upstream input to immune balance. Epitalon restores pineal function and indirectly supports immune diurnal rhythm.
Protocols
Recurrent-infection (8 weeks): Thymosin Alpha-1 1.6 mg SC twice weekly. Track infection frequency and severity. Repeat annually if useful.
Chronic inflammatory (12 weeks): KPV 250 mcg SC daily + BPC-157 250 mcg SC daily. Track inflammatory markers (hsCRP, ESR) at baseline and at 6 weeks.
Immune support during cancer treatment: Thymosin Alpha-1 1.6 mg SC twice weekly, in coordination with oncologist.
Safety
Thymosin Alpha-1 has an extensive clinical safety record across decades. LL-37 is generally well-tolerated; some users report mild fatigue during early dosing. KPV is well-tolerated; mild flushing possible at high doses. Active autoimmune disease may complicate immune-peptide use — clinical guidance recommended.
References
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009.
- Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Mol Immunol. 2012. PMID: 22921356.
- Catanzaro D, et al. Anti-inflammatory peptides — case of KPV. 2015.
What the evidence actually shows
The immune peptide literature has a particular shape: strong mechanistic plausibility from animal studies, robust clinical data for specific disease applications (Thymosin Alpha-1 in HBV, HCV), and limited controlled data for the "general immune health" use case most consumers care about. This is similar to the GH-axis literature — the disease-state evidence is real, but extrapolation to the well population is more practitioner-art than published-science.
A 2020 meta-analysis of Thymosin Alpha-1 in viral hepatitis (covering 11 RCTs, n=857) found significant improvements in viral clearance and sustained virological response. The transferability of that signal to other contexts — say, prevention of seasonal viral illness, or post-infection recovery — is the open question. The answer, on the evidence available, is: probably yes, but the effect size is smaller and the indication looser. This is why the immune peptides are most defensibly used in specific contexts (chronic infection, immunocompromise, autoimmune dysregulation) rather than as general "wellness" interventions.
Where to source
Immune peptides have particular sensitivity to manufacturing quality. Endotoxin contamination — common in low-purity peptide preparations — produces immune effects that have nothing to do with the peptide itself and can confound results or cause harm. Always source from verified vendors with endotoxin testing per batch (LAL test below 0.5 EU/mg).
Monitoring
For chronic-condition use cases, baseline and follow-up labs should include CBC with differential, comprehensive metabolic, hsCRP, IL-6, and where relevant the disease-specific markers (HBV/HCV viral load, antinuclear antibody panels, etc.). Subjective measures: infection frequency log, symptom severity scales appropriate to the condition.